Want to see KR:249420 full AI Analyst Report?
Top Page
Ildong Pharmaceutical Co., Ltd.
(249420)
Select Model
Select Model
Rating:60Neutral
Price Target:
$13,283.00
Action:N/A
Date:10/28/26
The score is driven by improving financial performance from a multi-year turnaround and supportive valuation (low P/E with a dividend). These positives are tempered by weak technicals—price below all key moving averages with negative MACD—suggesting near-term market momentum is unfavorable.
Positive Factors
Profitability turnaround
The shift from substantial losses to positive and improving net income indicates that the turnaround is generating measurable earnings power. If maintained, this recovery can strengthen internal funding, support reinvestment, and improve resilience over the next several quarters.
Negative Factors
Negative operating profitability
Negative operating and EBITDA margins indicate that core operating performance remains under pressure even though reported net income is positive. This raises concerns about earnings quality and suggests that cost control or operating execution must improve before profitability can be considered durable.
Read all positive and negative factors
Positive Factors
Negative Factors
Profitability turnaround
The shift from substantial losses to positive and improving net income indicates that the turnaround is generating measurable earnings power. If maintained, this recovery can strengthen internal funding, support reinvestment, and improve resilience over the next several quarters.
Read all positive factors
Ildong Pharmaceutical Co., Ltd. (249420) vs. SPDR S&P 500 ETF (SPY)
Market Cap
₩404.42B
Dividend Yield1.56%
Average Volume (3M)111.61K
Price to Earnings (P/E)9.0
Beta (1Y)0.29
Revenue Growth-0.65%
EPS GrowthN/A
CountryKR
Employees1,104
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)1418.03
Shares Outstanding31,638,252
10 Day Avg. Volume90,172
30 Day Avg. Volume111,607
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)4.69
Price to Sales (P/S)2.04
P/FCF Ratio218.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)872
Revenue Forecast (FY)₩597.50B
Ildong Pharmaceutical Co., Ltd. Business Overview & Revenue Model
Company Description
Ildong Pharmaceutical Co., Ltd., established in 1941 and headquartered in Seoul, South Korea, is a company dedicated to the development, production, and distribution of a wide array of pharmaceutical products. Its extensive portfolio includes vari...
Ildong Pharmaceutical Co., Ltd. Financial Statement Overview
Summary
Income Statement
64
Positive
Balance Sheet
61
Positive
Cash Flow
58
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 582.33B | 566.93B | 614.94B | 600.76B | 637.71B | 560.13B |
| Gross Profit | 223.57B | 214.76B | 233.46B | 207.54B | 236.34B | 219.44B |
| EBITDA | -5.52B | 39.90B | 33.59B | -51.23B | -80.49B | -101.34B |
| Net Income | 43.61B | 27.66B | -4.58B | -78.93B | -142.17B | -99.71B |
Balance Sheet | ||||||
| Total Assets | 560.50B | 573.03B | 589.04B | 611.26B | 655.81B | 708.97B |
| Cash, Cash Equivalents and Short-Term Investments | 60.37B | 64.96B | 84.87B | 81.28B | 78.75B | 154.68B |
| Total Debt | 142.05B | 150.31B | 205.55B | 212.73B | 207.75B | 226.16B |
| Total Liabilities | 310.95B | 333.52B | 429.99B | 437.00B | 457.59B | 548.39B |
| Stockholders Equity | 257.95B | 246.42B | 160.76B | 169.54B | 191.24B | 152.91B |
Cash Flow | ||||||
| Free Cash Flow | 23.73B | 5.30B | 14.24B | -54.80B | -73.15B | -31.16B |
| Operating Cash Flow | 35.44B | 18.95B | 28.29B | -36.62B | -53.54B | -11.37B |
| Investing Cash Flow | -4.20B | -2.28B | 18.46B | -20.36B | -26.44B | -43.37B |
| Financing Cash Flow | -36.45B | -24.09B | -27.85B | 58.15B | -3.29B | 104.32B |
Ildong Pharmaceutical Co., Ltd. Technical Analysis
Negative
―
Price Trends
14280.40
Negative
15167.50
Negative
23165.61
Negative
Market Momentum
-478.61
Positive
39.60
Neutral
14.51
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KR:249420, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 13559.00, equal to the 50-day MA of 14280.40, and equal to the 200-day MA of 23165.61, indicating a bearish trend. The MACD of -478.61 indicates Positive momentum. The RSI at 39.60 is Neutral, neither overbought nor oversold. The STOCH value of 14.51 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KR:249420.
Ildong Pharmaceutical Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | ₩560.29B | 5.53 | ― | 2.80% | 10.50% | 96.29% | |
61 Neutral | ₩581.17B | 6.94 | ― | 1.94% | 10.06% | -3.74% | |
60 Neutral | ₩404.42B | 8.96 | ― | 1.56% | -0.65% | ― | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
51 Neutral | ₩435.39B | -884.82 | ― | 0.08% | 6.21% | 95.65% | |
50 Neutral | ₩369.99B | 64.89 | ― | 3.33% | 22.17% | -38.54% | |
46 Neutral | ₩332.73B | -56.26 | ― | 2.01% | 15.38% | ― |
* General Sector Average
KR:249420
Ildong Pharmaceutical Co., Ltd.
12,790.00
-9,511.57
-42.65%
KR:000640
Dong-A Socio Holdings Co., Ltd.
87,600.00
-15,811.93
-15.29%
KR:001060
JW Pharmaceutical Corporation
23,200.00
533.84
2.36%
KR:003000
Bukwang Pharmaceutical Co., Ltd.
3,750.00
177.39
4.97%
KR:019170
Shinpoong Pharmaceutical Co., Ltd.
8,460.00
-5,070.00
-37.47%
KR:170900
Dong-A ST Co., Ltd.
34,900.00
-9,625.21
-21.62%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.